The ENTB model is currently the fastest way to actual revenue and real share growth. Low float in this company will propel it to new heights once news hits. BMSN will have a much longer(years) road ahead given the development and clinical phases of a new drug and will not generate revenue until the drug is approved. Drug development takes a long time and is expensive(millions). Hope for a partner there. Of course there will excitement if the FDA grants BMSN approval to start. Check out the IND process.